Amakuru rusange
Poroteyine Yatewe na Vitamine K Kubura cyangwa Antagonist-II (PIVKA-II), izwi kandi nka Des-γ-carboxy-prothrombine (DCP), ni uburyo budasanzwe bwa prothrombine.Mubisanzwe, prothrombine 10 isigara ya glutamic aside (Glu) murwego rwa γ-carboxyglutamic aside (Gla) kumwanya wa 6, 7, 14, 16, 19, 20,25, 26, 29 na 32 ni γ-karubasi ya Gla na vitamine. -K biterwa na gl- glutamyl carboxylase mu mwijima hanyuma ikinjira muri plasma.Ku barwayi barwaye kanseri ya hepatocellular (HCC), car-carboxylation ya prothrombine irabangamiwe ku buryo PIVKA-II iba mu mwanya wa prothrombine.PIVKA-II ifatwa nkaho ari biomarker ikora neza kuri HCC.
Icyifuzo | CLIA (Gufata-Kumenya): 1E5-1 ~ 1D6-10 1E5-1 ~ 1E6-7 |
Isuku | > 95%, bigenwa na SDS-PAGE |
Buffer | 20 mM PB, 150 mM NaCl, 0.1% Proclin 300, pH7.4 |
Ububiko | Ubike mubihe bidasanzwe kuri -20 ℃ kugeza -80 ℃ umaze kwakira. Kububiko bwigihe kirekire, nyamuneka aliquot uyibike.Irinde gukonjesha inshuro nyinshi. |
izina RY'IGICURUZWA | Injangwe.Oya | Indangamuntu ya Clone |
PIVKA-Ⅱ | AB0009-1 | 1F4-5 |
AB0009-2 | 1E5-1 | |
AB0009-3 | 1D6-10 | |
AB0009-4 | 1E6-7 |
Icyitonderwa: Bioantibody irashobora kugereranya ingano kubyo ukeneye.
1.Matsueda K, Yamamoto H, Yoshida Y, n'abandi.Kanseri ya Hepatoide ya pancreas itanga proteyine iterwa na vitamine K idahari cyangwa antagonist II (PIVKA-II) na α-fetoprotein (AFP) [J].Ikinyamakuru cya Gastroenterology, 2006, 41 (10): 1011-1019.
2.Viggiani, Valentina, Palombi, 等.Poroteyine ziterwa na vitamine K idahari cyangwa antagonist-II (PIVKA-II) yiyongereye cyane ku barwayi ba kanseri ya hepatocellular yo mu Butaliyani. [J].Ikinyamakuru cya Scandinaviya cya Gastroenterology, 2016.
3.Simundic AM.Ibyifuzo bifatika byo gusesengura imibare no kwerekana amakuru mu kinyamakuru cya Biochemia Medica [J].Biochemia Medica, 2012, 22 (1).
4.Tartaglione S, Pecorella I, Zarrillo SR, n'abandi.Poroteyine Yatewe na Vitamine K Kubura II (PIVKA-II) nka biomarker ishobora kuba kanseri ya kanseri yandura: ubushakashatsi bwikigereranyo [J].Biochemia Medica, 2019, 29 (2).